Clinical Study of Redirected Autologous T Cells with a BCMA-targeted Chimeric Antigen Receptor in Patients with Refractory or Relapsed Multiple Myeloma

Trial Profile

Clinical Study of Redirected Autologous T Cells with a BCMA-targeted Chimeric Antigen Receptor in Patients with Refractory or Relapsed Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs CAR-BCMA-T-cell (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms XHEC-C-2017-027-2
  • Most Recent Events

    • 15 Dec 2017 Planned End Date changed from 30 Nov 2020 to 30 Sep 2020.
    • 15 Dec 2017 Planned primary completion date changed to 30 Sep 2019.
    • 24 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top